We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+14.19%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$689M
AUM Growth
-$53.2M
Cap. Flow
-$90.8M
Cap. Flow %
-13.19%
Top 10 Hldgs %
41.31%
Holding
80
New
3
Increased
6
Reduced
50
Closed
5

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$20.9M
2
JUNO
Juno Therapeutics, Inc.
JUNO
+$13.9M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$9.22M
4
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$6.73M
5
CHRS icon
Coherus Oncology
CHRS
+$2.49M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$22.7M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$15.6M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$10.7M
4
HRTX icon
Heron Therapeutics
HRTX
+$10.4M
5
BPMC
Blueprint Medicines
BPMC
+$8.66M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Miscellaneous 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
76
DELISTED
Astria Therapeutics
ATXS
– –
-13,333
Closed -$2.89M
NGNE icon
77
Neurogene
NGNE
$678M
– –
-7,592
Closed -$2.51M
NSTG
78
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-40,490
Closed -$903K
CNCE
79
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-538,422
Closed -$5.54M
AGTC
80
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-17,321
Closed -$162K
1 2 3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Cormorant Asset Management held 80 positions worth $689M, down 7.2% from $742M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management withdrew a net $90.8M in Q1 2017, closing 5 positions and reducing 50 holdings. Its most notable exit was Concert Pharmaceuticals, Inc., an estimated $5.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in AnaptysBio worth $24.9M.

  • Cormorant Asset Management's largest Q1 2017 buy was AnaptysBio: 895,626 shares worth $24.9M.
  • Cormorant Asset Management added most to Forward Pharma A/S American Depositary Shares in Q1 2017, an estimated $6.73M increase.
  • Cormorant Asset Management's biggest Q1 2017 reduction was NEVRO CORP., cutting an estimated $22.7M.
  • Cormorant Asset Management fully exited Concert Pharmaceuticals, Inc. in Q1 2017, selling an estimated $5.54M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $689M portfolio in Q1 2017.
  • Cormorant Asset Management opened 3 new positions and closed 5 in Q1 2017.
  • Cormorant Asset Management's portfolio value fell 7.2% quarter-over-quarter to $689M.

Based on Cormorant Asset Management's 13F filing for Q1 2017, filed 15 May 2017.